Form 4: Vertex Pharmaceuticals EVP Charles Wagner Sells Shares Under 10b5-1 Trading Plan

Charles Wagner, EVP & Chief Financial Officer of Vertex Pharmaceuticals, sold 3,250 shares of common stock at $460 per share on June 3, 2024, under a pre-arranged trading plan.

Summary

• Charles Wagner, the EVP & Chief Financial Officer of Vertex Pharmaceuticals, sold 3,250 shares of common stock on June 3, 2024.
• The sale was executed at a price of $460 per share.
• Following the transaction, Wagner directly owns 47,137 shares of Vertex Pharmaceuticals.
• The transaction was conducted under a company-approved trading plan established on February 26, 2024, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often related to personal financial planning. The use of 10b5-1 trading plans allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options and grants, leading to periodic sales of shares.
• Rule 10b5-1 trading plans are a standard practice among executives to manage their stock holdings and avoid insider trading concerns.
• Comparing Wagner's transactions to those of executives at similar pharmaceutical companies like Gilead Sciences (GILD) or Amgen (AMGN) would provide further context, but this data is not provided in the document.

Stakeholder Impact

• The stock sale by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the pre-planned nature of the transaction.

Key Dates